A recent study published in The Journal of Pathology Clinical Research highlights the impact of MYCN amplification on survival outcomes in isocitrate dehydrogenase-mutant gliomas. Analyzing 190 patients, researchers found MYCN amplification in 14.7 percent of cases, closely linked to higher tumor grades and reduced survival rates, especially in lower-grade tumors. Patients with MYCN-amplified gliomas had an average survival of 91.1 months compared to 112.1 months for non-amplified cases. The study suggests that lower-grade tumors with MYCN amplification should be reclassified as grade 4 to improve prognostic accuracy.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
